The questions most often asked on the road from diagnosis to treatment: which test is requested when, what decisions rest on, and how the process runs. Each article takes a single question and is published with its sources.
Diagnosis and TreatmentTargeted therapy resistance develops when a tumour finds a new escape route. How the mechanism is identified and what decides the next line of treatment.
Read the Article
Diagnosis and TreatmentctDNA testing looks for tumour DNA in blood after surgery. What minimal residual disease means and how the result shapes the chemotherapy decision.
Read the Article
Diagnosis and TreatmentWhat stage 4 cancer means, how metastatic disease is defined and what the label does not tell you: staging logic, differences by type and treatment options.
Read the Article
Diagnosis and TreatmentWhat an early access programme is, how named-patient import works and what taking part in a clinical trial actually offers. Four routes compared.
Read the Article
Diagnosis and TreatmentWhat early detection of cancer actually changes, the screening schedule used in Türkiye, and the harms of screening, set out with randomised evidence.
Read the Article
Diagnosis and TreatmentHow to get a second opinion in cancer, which documents are needed and how to make the consultation productive. Timing, preparation and what to expect.
Read the Article
Diagnosis and TreatmentHow a tumour board works, who sits on it and who makes the decision, with figures on how often board review changes the diagnosis and the treatment plan.
Read the Article
Diagnosis and TreatmentWho should have HPV screening, at what age and how often? What a positive result means and what the vaccine has actually achieved, with the evidence.
Read the Article
Diagnosis and TreatmentWhat personalised cancer treatment really refers to, which information it rests on and whether it is possible for every patient. The limits and the evidence.
Read the Article
Diagnosis and TreatmentWhen the tissue biopsy falls short, plasma ctDNA opens a route to molecular diagnosis. Agreement is low for fusions and a negative result sends you back.
Read the Article
Diagnosis and TreatmentThe number of cycles follows guideline protocols set by cancer type, stage and the aim of treatment. How duration differs in adjuvant, neoadjuvant and metastatic disease.
Read the ArticleOther Headings: Genetic and Molecular Oncology · Cancer Types · Life and Support · Oncology News · All Articles
You can send your pathology and imaging reports on WhatsApp or by email. Documents are reviewed before the consultation.
